Acecann
Founded 2019 · 21 employees on LinkedIn · 4 known investors
AceCann cultivates, processes, and extracts medical cannabis products aimed at the European market. The company produces its products to pharmaceutical standards for use in the medical cannabis sector.
Also known as AceCann
Investors · 4
Company profile
researched Aug 2026AceCann is a medical cannabis company focused on the cultivation, processing and extraction of medical cannabis products for the European market. Its operations span four stated activity areas: indoor cultivation in a custom-engineered facility using craft techniques to produce GACP-compliant flower; post-harvest processing in an EU-GMP certified facility covering drying, trimming, curing and packaging; extraction of extracts and oils; and research and development.
The company positions its output at pharmaceutical standards, offering GMP I and II certified finished products as well as contract manufacturing for third parties under GACP compliance. Its research and development work covers new medical applications of cannabis and advanced tissue culture aimed at improving plant health, optimising genetics and identifying cultivars for targeted therapeutic use. AceCann states a mission of improving lives through high-quality and innovative medical cannabis products and a vision of becoming Europe's most trusted medical cannabis company.
Founding story
AceCann was established by three co-founders and investors — Frederico Brito e Abreu, Pedro Trinité and Tiago Bartolomeu — who also serve as board members and bring backgrounds in private equity, entrepreneurship and the pharmaceutical/healthcare industry (including Advent International, McKinsey & Company, Teman Capital, TTR and Sandoz).
Business model
AceCann produces medical cannabis flower, extracts and oils to pharmaceutical standards, selling finished GMP I and II certified products and additionally providing contract manufacturing services to third parties under GACP compliance.
Revenue is derived from sales of finished medical cannabis products (flower, extracts and oils) and from contract manufacturing performed for third parties.
Traction
The company reports operating cultivation, EU-GMP certified processing and extraction facilities and offers contract manufacturing to third parties; no quantified operational or financial metrics are disclosed by the company.
Latest developments
AceCann's stated focus is growth of business operations, capital raising to support that growth, and operational build-out of its manufacturing, R&D and go-to-market functions.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
AceCann describes itself as differentiated within the growing European medical cannabis market by producing to pharmaceutical standards and by its solvent-free extraction technology, and aims to become Europe's most trusted medical cannabis company.
AceCann cites production to pharmaceutical standards (EU-GMP certified processing, GACP-compliant cultivation, GMP I and II finished products), a solvent-free extraction technology it describes as unique in Europe, and in-house intellectual property and tissue culture capability.
Technology
The company operates an indoor, custom-engineered cultivation facility producing GACP-compliant flower and an EU-GMP certified processing facility handling end-to-end drying, trimming, curing and packaging. Its extraction process is described as solvent-free and, per the company, the only such technology in Europe, intended to retain cannabinoids and terpenes in extracts and oils. R&D includes advanced tissue culture for plant health and genetics optimisation, supported by company intellectual property.
Go-to-market
AceCann sells finished pharmaceutical-standard medical cannabis products into the European medical cannabis market and complements this with contract manufacturing for other operators; the company maintains dedicated sales and commercial leadership functions.
Medical cannabis patients in Europe, reached via the medical channel, together with third-party companies purchasing contract manufacturing and processing services.
Geography
The company targets the European market and lists a Portuguese contact telephone number (+351), with team backgrounds concentrated in Portugal.
History
The company has built out cultivation, EU-GMP certified processing, extraction and R&D functions, assembling a management team covering cultivation and tissue culture, post-harvest and manufacturing, extraction, sales, finance, compliance and quality assurance, including a designated Qualified Person and a facility manager. Leadership figures named by the company include CEO Ivanshu Shantilal in the management team listing and Pedro Gomes described as CEO leading growth strategy, capital raises and operational build-out, alongside CFO Luis Brito e Abreu, CCO Sebastian de la Rosa and CSO José Ascensão.
Risks & controversies
As a medical cannabis producer, AceCann's operations depend on maintaining pharmaceutical-grade certifications, including GACP compliance and EU-GMP certification for processing and GMP I and II certification for finished products.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
In the news
▸Research sources · 1
primary sources listed
- Acecannacecann.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Acecann do?
- AceCann is a Portugal-based medical cannabis company cultivating, processing and extracting products for the European market.
- Who are Acecann's investors?
- Acecann's investors include Amaral Family Investments, BlueCrow Capital, Casa Verde Capital, Lince Capital.